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Interpretive summary: Hyperketonemia during LPS induced mastitis affects systemic and 1 
local intramammary metabolism in dairy cows. By Zarrin et al. Effects of an induced 2 
hyperketonemia during an intramammary lipopolysaccharide (LPS) challenge on systemic 3 
and local mammary metabolism in mid-lactation dairy cows demonstrated that 4 
hyperketonemia had no effect on mammary metabolism. Induced intramammary LPS mastitis 5 
increased plasma glucose, cortisol, glucagon, insulin concentration, and decreased plasma 6 
beta-hydroxybutyrate (BHBA) concentration while plasma glucose and glucagon increased 7 
less in the BHBA treated animals than in controls. The results indicate that BHBA infusion 8 
decreases glucose as an energy source for the immune system through the decline of glucagon 9 
which may reflect the negative effect of spontaneous hyperketonemia on metabolic 10 
adaptations during mastitis in dairy cows. 11 
 12 
HYPERKETONEMIA AND MAMMARY LPS CHALLENGE  13 
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ABSTRACT 33 
Hyperketonemia interferes with the metabolic regulation in dairy cows. It is assumed that 34 
metabolic and endocrine changes during hyperketonemia affect also metabolic adaptations 35 
during inflammatory processes. We have therefore studied systemic and local intramammary 36 
effects of elevated plasma beta-hydroxybutyrate (BHBA) before and during the response to an 37 
intramammary lipopolysaccharide (LPS) challenge. Thirteen dairy cows received 38 
intravenously either a Na-DL-β-OH-butyrate infusion (HyperB, n=5) to achieve a constant 39 
plasma BHBA concentration (1.7 ± 0.1 mmol/L), adjustments of the infusion rates were made 40 
based on immediate measurements of plasma BHBA every 15 min, or an infusion with a 0.9 41 
% NaCl solution (Control, n=8) for 56 h. Infusions started at 0900 am on day 1 and continued 42 
until 0500 pm two days later. Two udder quarters were challenged with 200 μg Escherichia 43 
coli-LPS and two udder quarters were treated with 0.9 % saline solution as control quarters at 44 
48 h after the start of infusion. Blood samples were taken at one week and 2 h before the start 45 
of infusions as reference samples and hourly during the infusion. Mammary gland biopsies 46 
were taken one week before, 48 h, and 56 h (8 h after LPS challenge) after the start of 47 
infusions. The mRNA abundance of key factors related to BHBA and fatty acid metabolism, 48 
and glucose transporters was determined in mammary tissue biopsies. Blood samples were 49 
analyzed for plasma glucose, BHBA, non-esterified fatty acid (NEFA), urea, insulin, 50 
glucagon, and cortisol concentration. Differences were not different for effects of BHBA 51 
infusion on the mRNA abundance of any of the measured target genes in the mammary gland 52 
before LPS challenge. Intramammary LPS challenge increased plasma glucose, cortisol, 53 
glucagon, and insulin concentration in both groups (P<0.05) but increases in plasma glucose 54 
and glucagon concentration were less pronounced in HyperB than in controls (P<0.05). In 55 
response to LPS challenge plasma BHBA concentration decreased in controls (P<0.05), and 56 
decreased also slightly in the BHBA infused animals because the BHBA concentration could 57 
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not be fully maintained despite a rapid increase of BHBA infusion rate (P<0.001). The 58 
change of mRNA abundance of citrate synthase (CS) in LPS-quarters, was significant 59 
between two treatment groups (P<0.05). Results indicate that elevated circulating BHBA 60 
inhibits gluconeogenesis before and during immune response to LPS challenge likely because 61 
BHBA can replace glucose as an energy source.  62 
 63 
INTRODUCTION 64 
The markedly increased energy and nutrient requirements at simultaneously inadequate feed 65 
intake results in a negative energy balance (NEB) at the onset of lactation (van Dorland et al., 66 
2009; Gross et al., 2011). A severe NEB leads to an increased mobilization of fat stores, an 67 
elevated uptake of NEFA by the liver, and an increase of plasma ketone body concentration 68 
(Bobe et al., 2004; Gross et al., 2011). The concentration of plasma BHBA, which is the 69 
major circulating ketone body in ruminants, is increased as a compensatory response to 70 
handle the excessive NEFA release during the NEB. Beta-hydroxybutyrate functions as 71 
energy source in many tissues, especially during NEB, and it seems also to be used for citrate 72 
synthesis in the mammary gland (Bionaz and Loor, 2008). An elevation of plasma BHBA 73 
concentration beyond the threshold of 1,200 µmol/L (Ospina et al., 2010) is generally 74 
accepted to represent the diagnosis of a subclinical ketosis (Duffield et al., 2009). The 75 
elevation of plasma ketone body concentration increases the risk of clinical ketosis, displaced 76 
abomasum, metritis and subsequent decrease of milk production (Duffield et al., 2009). 77 
Elevated plasma BHBA concentration had a positive correlation with the severity of E. coli 78 
mastitis in an in vitro study (Kremer et al., 1993), and the risk of mastitis was much higher in 79 
subclinically ketotic dairy cows (Oltenacu and Ekesbo, 1994). High elevation of plasma 80 
BHBA concentration more than physiological range impairs metabolism in animals (Müller et 81 
al., 1984; Schlumbohm and Harmeyer, 2004; Zarrin et al., 2013a). From the present study two 82 
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papers have been already published. Induced hyperketonemia was shown decrease two 83 
plasma glucose and glucagon concentrations while it did not affect milk yield, feed intake, 84 
insulin, NEFA, urea, cortisol, and enzymes involved in gluconeogenesis (Zarrin et al., 2013a). 85 
In addition, BHBA infusion caused increased acute phase protein mRNA abundance in the 86 
mammary gland but not in the liver. The LPS-related increase of somatic cell counts (SCC) 87 
was less pronounced whereas mRNA abundance of IL-8, IL-10 increased more in the 88 
response to LPS in the group receiving BHBA infusion than the control animals (Zarrin et al., 89 
2013b). 90 
The use of intramammary LPS challenge to simulate intramammary infection and to induce 91 
mastitis in dairy cows was established previously (Bruckmaier et al., 1993) to investigate the 92 
effect of mastitis on metabolism, immune responses, and performance in dairy cows. There is 93 
evidence that LPS challenge affects metabolism and mRNA abundance of inflammatory and 94 
other factors (Waldron et al., 2006; Bruckmaier et al., 1993; Vernay et al., 2012). In addition, 95 
it causes a decline of milk production (Bannerman et al., 2003). However, there is no 96 
information about effects of induced hyperketonemia at simultaneously even or positive 97 
energy balance on metabolic changes during mastitis.  98 
The objective was to induce long term hyperketonemia beyond the threshold (1.2 mmol/L) 99 
through BHBA infusion for 56 h, and additionally stimulate the immune system by 100 
intramammary LPS challenge to investigate systemic metabolic effects and changes of the 101 
mRNA abundance of genes related to metabolism in mammary tissue before and during the 102 
LPS challenge in mid-lactating dairy cows. Genes involved in fatty acid synthesis (fatty acid 103 
synthase [FASN], acetyl-CoA carboxylase [ACoAC]), tricarboxylic acid cycle (CS), 104 
mammary BHBA metabolism (beta-hydroxybutyrate dehydrogenase 1 [BDH1], beta-105 
hydroxybutyrate dehydrogenase 2 [BDH2], Succinyl-CoA:3-ketoacid-coenzyme A transferase 106 
1 [OXCT1]), and glucose transporters (glucose transporter 1 [GLUT1], glucose transporter 4 107 
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[GLUT4]) were selected to investigate the effects of elevated BHBA at simultaneously 108 
reduced glucose on the mammary metabolism. 109 
 110 
MATERIAL AND METHODS 111 
Animals and Management  112 
The animal trials followed the Swiss Law on Animal Protection and were permitted by the 113 
Committee of Animal Experiments of the Canton Fribourg, Switzerland. In order to study the 114 
specific effect of BHBA infusion without the usual endocrine and metabolic changes during 115 
the transition period, thirteen multiparous Holstein dairy cows (parity 3.5 ± 0.1 Mean ± SEM) 116 
in a later lactational stage (28.0 ± 0.3 Mean ± SEM weeks of lactation) were selected. Before 117 
the start of experiments, health status of cows was checked by a routine blood glutaraldehyde 118 
coagulation test (Sandholm, 1976) and by measuring milk somatic cell count (DeLaval cell 119 
counter DCC, Delaval International AB, Tumba, Sweden), which had to be less than 150 x 120 
10
3
 cells/mL in all four quarters. Milking was performed twice daily at 0530 h and 1600 h.  121 
Two weeks before the start of the experiment animals were kept in a tie stall barn for 122 
adaptation to the environment and feeding situations. All animals were fed ad libitum with 123 
hay (dry matter [DM] content, 890 g/kg of fresh matter [FM]; on DM basis, consisting of 153 124 
g of crude protein [CP]/kg, 235 g of crude fiber [CF]/kg, and 5.7 MJ of NEL/kg). In addition 125 
they received a protein- and energy-rich concentrate (23.5% barley, 14.0% oats, 20.0% wheat 126 
bran, 17.0% soybean expeller, 15.0% linseed meal, 0.6% salt, 2.2% carbonate of lime, 0.4% 127 
calf rearing feed premix, 4.0% molasses and 3.0% by-pass fat, DM content, 881 g/kg of FM; 128 
on DM basis, consisting of 217 g of CP/kg, 73.9 g of CF/kg, and 7.6 MJ of NEL/kg) twice 129 
daily according to individual milk production. Cows had free access to fresh water and 130 
minerals (50 g/cow) were supplied daily.  131 
 132 
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Experimental design and treatments 133 
Thirteen dairy cows were randomly assigned to two treatment groups. One group was 134 
intravenously infused with a pyrogen-free and pH-balanced Na-DL-β-OH-butyrate (HyperB, 135 
n=5) to achieve an elevated plasma BHBA concentration (1.5 to 2.0 mmol/L) while the other 136 
group received a 0.9 % saline solution (Control, n=8) for 56 h. The infusions started at 0900 137 
am on day 1 and continued to 0500 pm two days later. Details on the preparation of solutions 138 
and infusion procedures are explained elsewhere (Zarrin et al., 2013a).  139 
At 48 h of infusions, two udder quarters were injected through the teat canal with 10 mL 140 
physiological NaCl (0.9 %) include 200 µg of LPS Escherichia coli serotype 026:B6 (# 141 
L8274; Sigma-Aldrich, St. Louis, MO) as LPS quarters, and 10 mL 0.9 % NaCl were injected 142 
in two udder quarters as control. Details are described elsewhere (Vernay et al., 2012). 143 
 144 
Data collection and sampling 145 
Blood samples. Blood samples were taken one week and 2 h before the start of infusions at 146 
0730 h, after milking and before feeding, as reference samples and with sampling continuing 147 
hourly during the entire infusion period. On day before the start of infusions cows were fitted 148 
with indwelling intravenous catheters (Cavafix® Certo® Splittocan®, B. Braun Melsung AG, 149 
Germany) with a length of 32 cm and a diameter of 16 G in both jugular veins. Blood samples 150 
were collected into tubes, containing tri-potassium-EDTA, from the contralateral jugular 151 
catheter, which was not used for the infusion. Samples were immediately put on wet ice, 152 
centrifuged for 20 min at 3,000 x g, at +4 °C and plasma was stored at -20 °C until analysis. 153 
During BHBA infusion, additional small blood samples (1mL) were taken and analyzed 154 
immediately for adjustment of BHBA infusion rates every 5 min for the first 2 h and 155 
thereafter every h. 156 
Udder biopsies. Details of the udder biopsy procedure were described by Vernay et al. (2012). 157 
In brief, one week before the start of infusions, before the LPS challenge (48 h after the start 158 
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of infusions), and at the end of infusion (56 h; 8 h after the LPS stimulation) udder tissue was 159 
taken from the two rear quarters (one LPS and one control quarter). Before the biopsies cows 160 
were sedated by an intravenous injection of 16 µg/kg of BW of xylazine (Xylazin Streuli ad 161 
us. vet.; G. Streuli & Co. AG, Uznach, Switzerland). Udder tissue (30 to 60 mg) was obtained 162 
under local anesthesia with 10 mL Lidocain 2% (Streuli Pharma AG, Uznach) using a biopsy 163 
needle (12 G x 10 cm; Bard
®
 Magnum
®
 Core Tissue Biopsy Needle, Türkenfeld, Germany). 164 
The samples were placed immediately into RNA stabilization reagent (RNAlater
®
, Ambion, 165 
Applied Biosysthems, Austin, TX), kept at +4 °C for 24 hours, and stored thereafter at –80 °C 166 
until RNA extraction.  167 
 168 
Laboratory procedures 169 
Blood variables. Plasma glucose, BHBA, NEFA, and urea concentrations were measured 170 
enzymatically with an automated analyzer (Cobas Mira 2, Hoffmann-La Roche, Basle, 171 
Switzerland) by commercial kits as described by van Dorland et al. (2009) and Kreipe et al. 172 
(2011). Plasma insulin was measured by radioimmunoassay (RIA) as described by Vicari et 173 
al. (2008), and total cortisol was measured by RIA as described by Blum et al. (1985). Plasma 174 
glucagon concentration was measured by using a commercial RIA kit (cat. # GL-32K, 175 
MILLIPORE, Zug, Switzerland). In addition the molar ratio of insulin: glucagon was 176 
calculated according the formula that suggested by Muller et al. (1971). 177 
Udder tissue. Total RNA was extracted from udder tissues with peqGOLD TriFast™ 178 
(PEQLAB Biotechnologie GmbH, Erlangen, Germany). Quantity and purity of RNA was 179 
measured by NanoDrop ND-2000 spectrophotometer (NanoDrop Technologies Inc., 180 
Wilmington, DE). Complementary DNA (cDNA) was synthesized by reverse transcription of 181 
one μg of total mRNA with Moleney Murine Leukemia Virus Reverse Transcriptase RNAase 182 
H Minus, Point Mutant (MMLV-RT; Promega Corp., Madison, WI) and random hexamer 183 
primers (Invitrogen, Leek, The Netherlands). The mRNA abundances of housekeeping genes 184 
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(glyceraldehyde 3-phosphate dehydrogenase [GAPDH] and ubiquitin) and target genes 185 
related to udder metabolism were measured by real-time quantitative PCR (qPCR) in a Rotor-186 
Gene 6000 rotary analyzer (Corbett Research, Sydney, Australia) and software version 1.7.75. 187 
The cycle threshold (CT) values obtained from candidate genes were adjusted according the 188 
mean of the housekeeping genes CT according to the following equation: ΔCT = CT 189 
(arithmetic mean of housekeeping genes) – CT (target gene). Differences in mRNA 190 
abundance of candidate genes (based on CT values) before the start of infusions and 48 h after 191 
the start of infusions were calculated: ΔΔCT = ΔCT [d 3 (0 h)] – ΔCT [d 0], and differences 192 
in mRNA abundance by LPS challenge were calculated for LPS and control quarters 193 
separately according to this equation: ΔΔCT = ΔCT [d 3 (8 h)] – ΔCT [d 3 (0 h)]. The primer 194 
sequences for FASN, CS, ACoAC, BDH2, GLUT1, and GLUT4 were published elsewhere 195 
(Graber et al., 2010). Succinyl-CoA:3-ketoacid-coenzyme A transferase 1 (OXCT1) and 196 
BDH1 primers were designed to amplify cDNA. Selected Primer sequences of housekeeping 197 
and measured genes encoding for mammary gland metabolism are shown in Table 1. The 198 
means ± SEM of mRNA levels of GAPDH and ubiquitin were stable across time points 199 
(baseline, 48 h after infusions, and at the end of infusions) and treatments (HyperB and NaCl) 200 
are shown in Table 2. 201 
 202 
Statistical analysis 203 
Before the statistical evaluation, all data tested for normality (SAS: proc univariate plot 204 
normal), and all parameters followed a normal distribution. The changes (differences between 205 
before and 48 h after the start of infusions, and before and after LPS administration) were 206 
calculated for mRNA abundance of target genes. Area under the curve (AUC) was calculated 207 
for blood variables during the LPS challenge (8.5 h) by the trapezoidal rule (combination of 208 
rectangular and triangular area compartments). The respective plasma concentration before 209 
the start of infusion was used as baseline value. 210 
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The changes of mRNA abundance of measured genes and AUC of blood variables were 211 
analyzed by using the general linear models (GLM) procedure of SAS (SAS Institute Inc., 212 
Cary, NC, USA, 2002-2008, Release 9.2), including treatment (BHBA or NaCl) as fixed 213 
effect. Differences between means were localized by Tukey’s test. In addition, means of delta 214 
values obtained within each treatment were tested for their difference from “0”. Differences in 215 
blood plasma variables between treatments within each time point and between time points 216 
within treatments were evaluated by using the MIXED procedure of SAS, including treatment 217 
(BHBA or NaCl), time, and their interaction as fixed effects, and cows as repeated subject. 218 
Tukey-Kramer test was used for adjustment of multiple comparisons. The Compound 219 
Symmetry (CS) structure was used for variance-covariance matrix for repeated measures 220 
within animals. 221 
Data are presented as means ± SEM and differences were considered significant if P<0.05.  222 
 223 
RESULTS 224 
Infusion rates and concentration of plasma variables, feed intake, and milk yield  225 
Area under the curve of plasma variables concentration in HyperB and control group during 226 
the LPS challenge (8.5 h) is shown in Table 4. Mean BHBA infusion rate and plasma BHBA 227 
concentration in HyperB and control group during -24 to -48 h of infusion and hourly after 228 
LPS challenge is shown in Figure 1. The mean infusion rate of BHBA over 48 h was 8.1 ± 0.3 229 
µmol/kg/min. During 48 h BHBA infusion mean plasma BHBA concentration was 230 
maintained at 1.7 ± 0.1 mmol/L in HyperB group, and plasma BHBA concentration in the 231 
control group was 0.6 ± 0.1 mmol/L. Intramammary LPS challenge decreased plasma BHBA 232 
concentration in HyperB from 1.7± 0.1 to 1.4 ± 0.1 mmol/L (P<0.001) despite increase 233 
infusion rate. In control group plasma BHBA decreased from 0.6 ± 0.1 to 0.4 ± 0.1 mmol/L 234 
(P<0.01) compared with before LPS challenge. Because of adjustment BHBA infusion rate to 235 
maintain hyperketonemia in the HyperB group, mean BHBA infusion rate needed to be 236 
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significantly increased (P<0.001) to 11.1 µmol/kg/min after the LPS administration. Despite 237 
the increased BHBA infusion rate in HyperB, plasma BHBA concentration decreased in both 238 
groups (P<0.05) i.e. due to the fast change of BHBA plasma concentration the maintenance 239 
of hyperketonemia in the HyperB through increased infusion rate was not completely 240 
successful. 241 
As previously reported (Zarrin et al., 2013a) dry matter intake (DMI) and milk yield were not 242 
affected by 48 h BHBA infusion. Intramammary LPS challenge decreased DMI and milk 243 
yield in both treatment groups, whereas these variables were not affected by treatments (Table 244 
3).   245 
Plasma glucose, glucagon,  insulin, NEFA, urea, and cortisol concentration and molar ratio of 246 
insulin: glucagon before the LPS challenge (average of 24-48 h of infusion), hourly after LPS 247 
stimulation (8.5 h), and their differences within treatments and between each time points are 248 
shown in Figures 2A, 2B, 2C, 3A, 3B, 3C, 4. Compared to plasma glucose concentration 249 
before the LPS challenge, intramammary LPS administration caused an increase of plasma 250 
glucose concentration in both infusion groups up to 90 min. Plasma glucose concentration 251 
was decreased at 150 min after the LPS challenge, after that increased again at 210 min, and 252 
finally decreased to the same concentration as before LPS administration. The increase of 253 
plasma glucose concentration after LPS administration was lower in HyperB than in the 254 
Control (P<0.05; Figure 2A; Table 4). 255 
On the second day of hyperketonemia, treated cows had on average lower glucagon 256 
concentrations than control cows. Intramammary LPS treatment increased after 3.5 h 257 
glucagon concentration, which persisted for the remaining sampling period (8.5 h). During 258 
this time period, glucagon concentrations were lower in hyperketotic than control cows 259 
(P<0.05; Figure 2B), indicating that hyperketonemia attenuates the LPS-induced glucagon 260 
secretion (P<0.05; Table 4).  261 
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In comparison with 48 h BHBA infusion, plasma insulin increased (P<0.05; Figure 2C) in 262 
response to LPS challenge and reached a peak at 210 min in HyperB and at 270 min in control 263 
group, respectively. Based on AUC plasma insulin concentration did not differ between 264 
HyperB and control group (Table 4). 265 
Plasma NEFA concentration was not affected by the LPS challenge and BHBA infusion 266 
(Figure 3A; Table 4). 267 
Intramammary LPS administration induced a decrease of plasma urea concentration only in 268 
the first 90 min after the LPS challenge in HyperB group, whereas LPS challenge decreased 269 
that in the first 30 min in control group (P<0.05; Figure 3B). Urea concentrations were not 270 
affected by treatments infusion (Table 4). 271 
Plasma cortisol concentration was increased at 90 min after the intramammary LPS 272 
stimulation in both treatment groups (P<0.05; Figure 3C), but based on AUC cortisol did not 273 
differ between HyperB and control group (Table 4). 274 
Insulin: glucagon molar ratio was not affected by the treatments at second day of infusion and 275 
during the LPS challenge, while it affected by intramammary LPS challenge at 3.5 h and 4.5 h 276 
in HyperB and control groups, respectively (Figure 4; Table 4). 277 
 278 
mRNA abundance of candidate genes related to mammary gland metabolism  279 
mRNA abundance related to mammary metabolism during the 48 h of BHBA infusion. The 280 
mRNA abundance of genes related to mammary gland metabolism before and 48 h after the 281 
start of infusions are shown in Table 4. Fatty acid synthase mRNA abundance decreased 282 
within the HyperB group during 48 h of BHBA infusion (P<0.05; Table 4). The mRNA 283 
abundances of the other candidate genes were not affected by 48 h BHBA infusion.  284 
mRNA abundance of genes related to mammary metabolism during the LPS challenge. For 285 
both groups, differences between mRNA abundance of genes related to mammary gland 286 
metabolism before and after the LPS challenge in quarters stimulated with intramammary 287 
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LPS and control quarters are shown in Table 4. Citrate synthase mRNA abundance in LPS 288 
quarters increased in HyperB and decreased in control group after the LPS challenge (P<0.05; 289 
Table 6). Intramammary LPS challenge decreased mRNA abundance of BDH2, FASN, and 290 
OXCT1 in LPS quarters of both treatment groups, and decreased BDH1 and GLUT4 mRNA 291 
abundance in control group (P<0.05). Infusion of BHBA decreased BDH2 mRNA abundance 292 
in control quarters in HyperB group (P<0.05) after the LPS challenge. The mRNA abundance 293 
of other candidate genes in control quarters were not affected by LPS challenge and BHBA 294 
infusion in both treatment groups.  295 
 296 
 297 
DISCUSSION 298 
To our best knowledge, this experiment is the first study to investigate effects of an induced 299 
long term (56 h) hyperketonemia, without other metabolic effects of NEB, on mammary gland 300 
metabolism, metabolic and endocrine parameters in combination with an activation of 301 
immune response by an intramammary LPS administration in mid lactating dairy cows. 302 
The effects of induced hyperketonemia for 48 h on blood metabolites, feed intake, mRNA 303 
abundance of candidate genes related to hepatic metabolism, and milk yield have been 304 
reported earlier (Zarrin et al., 2013a). The moderate effects of BHBA infusion on mammary 305 
gland metabolism at mRNA level confirms that milk synthesis was not affected by 306 
intravenous BHBA infusion in mid lactating dairy cows (Zarrin et al., 2013a). The lacking 307 
effect on milk synthesis was likely due to the related low needs of glucose for mammary 308 
lactose synthesis and other metabolic processes at this lactational stage compared to early 309 
lactation. Thus the reduced plasma glucose levels during BHBA infusion were likely not 310 
limiting for milk secretion.  311 
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Intramammary LPS challenge decreased plasma BHBA in both treatment groups. The goal to 312 
maintain plasma BHBA at 1.7 mmol/L through an increased BHBA infusion rate could not be 313 
achieved because the decline of plasma BHBA was faster than the adjustment of infusion rate 314 
was possible. Waldron et al. (2003) suggested that the decline of plasma BHBA concentration 315 
was related to the suppression of ruminal epithelium ketogenesis capacity after LPS 316 
challenge. Because the decline of BHBA after LPS administration was quite rapid and 317 
pronounced a contribution of changed ruminal absorption may be excluded. Despite not doing 318 
a mammary LPS challenge, intra-muscularly applied LPS in a different species decreased 319 
hepatic ketogenesis capacity (Memon et al., 1992) while LPS administration did not affect 320 
hepatic ketogenesis capacity in incubated liver slices of dairy cows (Waldron et al., 2003). 321 
Based on the fast and huge changes of plasma BHBA in BHBA infused animals in the present 322 
study this effect seems very unlikely. Recent findings showed that LPS challenge increased 323 
milk BHBA concentration in LPS treated quarters during an induced hyperketonemia 324 
(Lehmann et al., 2013). Thus a certain quantity of BHBA is lost with the secreted milk in LPS 325 
stimulated quarters. However, this portion does not seem to be quantitatively of great 326 
importance because milk secretion is reduced in the quarters treated with LPS.  327 
A transient increase and a subsequent decrease of plasma glucose concentration after LPS 328 
challenge in both groups in this study was consistent with previous studies that illustrated a 329 
transient hyperglycemia after E. coli endotoxin induced mastitis (Bruckmaier et al., 1993), 330 
increased and subsequent decreased plasma glucose concentration after LPS challenge 331 
(Werling et al., 1996). Hypoglycemia after the LPS challenge can also be attributed to 332 
increases of cytokines such as TNFα and IL-1β (Schmitz et al., 2004; Vernay et al., 2012; 333 
Zarrin et al., 2013b) that increase glucose utilization during the LPS challenge (Stouthard et 334 
al., 1995). Regarding to increase plasma glucose concentration after the LPS challenge, 335 
during a similar immune stimulation via LPS challenge previously, development of an insulin 336 
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resistance was reported, and in this case glucose infusion rate had to be reduced to avoid an 337 
increase of plasma glucose concentration, thus additional glucose was available through either 338 
glycogenolysis or gluconeogenesis (Vernay et al., 2012). Based on present data it seems that 339 
the initial increase plasma glucose concentration after LPS challenge is not related to the 340 
glycogenolysis, because LPS challenge increased plasma glucagon concentration 150 min 341 
after the LPS administration. The difference between plasma glucose concentrations in the 342 
two experimental groups after the LPS challenge is related to the BHBA infusion that 343 
decreased glucose production besides the decreased gluconeogenesis during LPS. The low 344 
plasma glucose concentration in HyperB rather than in the control group may be related to the 345 
reduced increase of plasma glucagon concentration in HyperB compared to the control group 346 
which resulted in low glucose production from gluconeogenesis or glycogen storage (Zarrin et 347 
al., 2013a). 348 
Intramammary LPS challenge did not affect plasma NEFA concentration in the present study. 349 
This finding is in agreement with a previous study that showed intramammary LPS challenge 350 
did not affect plasma NEFA concentration, whereas plasma NEFA concentration increased in 351 
control cows that received NaCl (Waldron et al., 2006). The results of the present study are in 352 
contrast with a previous study where different doses of LPS were administrated intravenously 353 
for 100 min in midlactating dairy cows and plasma NEFA tended to increase after LPS 354 
challenge (Waldron et al., 2003). In our previous study intramammary LPS challenge caused 355 
a decrease of plasma NEFA concentration in mid lactating dairy cows during hypoglycemic 356 
and euglycemic clamps which manipulated plasma glucose concentration (Vernay et al., 357 
2012). It can be assumed that in the present study the unaffected plasma NEFA concentration 358 
following LPS challenge is related to the use of BHBA as an alternative energy source which 359 
can diminish mobilization of fatty acids from fat stores in the HyperB group. 360 
15 
 
As previously observed in response to intramammary LPS administration (Lehtolainen et al., 361 
2003; Waldron et al., 2006; Vernay et al., 2012), plasma cortisol concentration increased in 362 
both treatment groups. Pro-inflammatory cytokines and possibly also the handling of the 363 
animals during the experiments likely activated the hypothalamus-pituitary-gland axis and 364 
increased the synthesis of glucocorticoids (Beishuizen and Thijs, 2003). Elevation of plasma 365 
cortisol concentration may be partially responsible for the observed induction of an insulin 366 
resistance (Andrews and Walker, 1999) to provide more glucose for the immune reaction. 367 
The increase of glucagon after LPS administration is in agreement with Waldron et al. (2003) 368 
who reported plasma glucagon concentration being increased at 2 h after the LPS challenge 369 
and stayed at a high level up to 8 h after the start of LPS challenge. In the current study 370 
increased plasma glucagon concentration in both groups was observed at 150 min after the 371 
intramammary LPS administration. However, the increase of plasma glucagon concentration 372 
during LPS challenge was much less in cows that received BHBA compared to Control. As 373 
reported previously, BHBA infusion decreased glucagon secretion (Zarrin et al., 2013a), that 374 
was probably mediated by the inhibitory effect of gamma amino butyric acid (GABA) on 375 
glucagon secretion (Adeghate et al., 2000; Wendt et al., 2004), which increased in the 376 
epileptic brain in present of high plasma BHBA concentration (Suzuki et al., 2009). The less 377 
pronounced increase of glucagon during LPS challenge in the HyperB group is likely related 378 
to a lower need of glucose for the immune response than in the control group, and thus less 379 
activation of gluconeogenesis. This effect is another indicator for BHBA to be an alternative 380 
energy source.  381 
An increased plasma insulin concentration in response to the LPS challenge in the present 382 
study is in agreement with previous studies (Waldron et al., 2003; Waldron et al., 2006; 383 
Vernay et al., 2012). Despite the inhibitory effect of insulin on glucagon secretion (Weir et 384 
al., 1976), plasma glucagon concentration increased after LPS challenge. The effect of LPS 385 
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challenge on glucoregulatory hormones is most likely related to effects of pro inflammatory 386 
cytokines (Eizirik et al., 1995; Andersson et al., 2001) which are stimulating the pancreatic 387 
production and release of these hormones. 388 
The effect of the intramammary LPS challenge on FASN, OXCT1, and BDH2 mRNA 389 
abundance in quarters stimulated with LPS in both groups, and decrease of CS mRNA 390 
abundance in the control group showed that LPS challenge negatively affects mammary gland 391 
metabolism and milk synthesis, which had been reported before (Waldron et al., 2003; 392 
Waldron et al., 2006). The increase of CS mRNA abundance in HyperB after LPS challenge 393 
is in agreement with Bionaz and Loor (2008) who suggested that the major product of BHBA 394 
metabolism in the bovine mammary gland is citrate which is increased in milk. It can be 395 
assumed that the upregulating of mammary gland CS mRNA abundance in HyperB group 396 
confirmed that BHBA can be partly used to produce energy through the tricarboxylic acid 397 
cycle by mammary gland (Palmquist et al., 1969). 398 
CONCLUSIONS 399 
Results demonstrate that BHBA represents an alternative energy source for the mammary 400 
tissues and for the immune system. With respect to milk secretion and the related specific 401 
need of glucose the BHBA induced adaptions may cause an inadequate decline of plasma 402 
glucose. It can be speculated that the resulting low plasma glucose concentration does also 403 
negatively affect the immune response. The current results may reflect the negative effect of 404 
spontaneous hyperketonemia on hepatic gluconeogenesis by providing less glucose. A long-405 
term reduced glucose availability caused by hyperketonemia might lower the productive 406 
performance of dairy cows. 407 
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Figures legends 
Figure 1. Mean beta-hydroxybutyrate (BHBA) infusion rate during -24 to -48 h infusion 
(24 - 48h inf) and hourly after LPS challenge (510 min) in BHBA cows 
(HyperB, n=5). Mean plasma BHBA concentration in cows infused with 
BHBA (HyperB) and control cows (NaCl, n=8) during 48 h infusion -24 to -48 
h average and hourly after LPS challenge (510 min). Values represent mean ± 
SEM. The open squares with plus show significant difference (P<0.05) of 
BHBA infusion rate during the LPS challenge to mean infusion rates in-24 to -
48 h. The close circles and open circles show significant differences (P<0.05) 
between -24 to -48 h average and each time point during the LPS challenge for 
HyperB, and NaCl group, respectively. The closed rectangle indicates 
significant difference between two treatment groups during LPS challenge 
(P<0.05). 
 
Figure 2. Mean plasma glucose (A), glucagon (B), and insulin (C) concentration in cows 
infused with BHBA (HyperB, n=5) and control cows (NaCl, n=8) during 48 h 
infusion (-24 to -48 h average) and hourly after LPS challenge (510 min). 
Values represent mean ± SEM. The close circles and open circles show 
significant differences (P<0.05) between -24 to -48 h average and each time 
point during the LPS challenge for HyperB, and NaCl group, respectively. The 
closed rectangle indicates significant difference between two treatment groups 
during LPS challenge (P<0.05). 
 
Figure 3. Mean plasma NEFA (A), urea (B), and cortisol (C) concentration in cows 
infused with BHBA (HyperB, n=5) and control cows (NaCl, n=8) during 48 h 
infusion (-24 to -48 h average) and hourly after LPS challenge (510 min). 
Values represent mean ± SEM. The close circles and open circles show 
significant differences (P<0.05) between -24 to -48 h average and each time 
point during the LPS challenge for HyperB, and NaCl group, respectively. The 
closed rectangle indicates significant difference between two treatment groups 
during LPS challenge (P<0.05). 
 
Figure 4. Insulin: glucagon molar ratio in cows infused with BHBA (HyperB, n=5) and 
control cows (NaCl, n=8) during 48 h infusion (-24 to -48 h average) and 
hourly after LPS challenge (510 min). Values represent mean ± SEM. The 
close circles and open circles show significant differences (P<0.05) between -
24 to -48 h average and each time point during the LPS challenge for HyperB, 
23 
 
and NaCl group, respectively. The closed rectangle indicates significant 
difference between two treatment groups during LPS challenge (P<0.05). 
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Plasma glucose concentration during the LPS challenge
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Plasma cortisol concentration during the LPS challenge
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Figure 4 Insulin:Glucagon molar ratio during the LPS challenge
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Table 1. Polymerase chain reaction primer information (for = forward, rev = reverse), annealing 
temperature and the PCR product length 
Gene
1
 Sequence 5’-3’ 
Gene Bank  
accession no. 
Anneal
ing  
temper
ature 
(°C) 
Length 
(bp) 
Fatty acid synthesis related variables 
ACoAC 
for CTCTTCCGACAGGTTCAAGC 
AJ-132890 61 248 
rev ACCATCCTGGCAAGTTTCAC 
FASN 
for CTGAGTCGGAGAACCTGGAG 
NM_001012669 63 232 
rev ACAATGGCCTCGTAGGTGAC 
Beta-hydroxybutyrate metabolism related variables 
BDH1 
for GAGTGAGAGCGGGTAAGGGT 
NM_001034600.2 61 199 
rev GGCCACAAAAGGCAGAATGG 
BDH2 
for TGCAACTGTGTGTGTCCAG 
NM_001034488.2 58 175 
rev CAGATTCATCAGAGGCCAAG 
OXCT1 
for ATGGTGACCTGGCTAACTGG 
NM_001076070.2 60 234 
rev TCAGACCCTTTTTGCTGTCC 
Citrate synthase 
CS 
for TGGACATGATGTATGGTGG 
BC-114138 60 217 
rev AGCCAAGATACCTGTTCCTC 
Glucose transporters  
GLUT1 
for GCTTCTCCAACTGGACTTCG 
NM_174602 60 225 
rev ACAGCTCCTCAGGTGTCTTG 
GLUT4 
for GACTGGTACCCATGTACGTG 
NM_174604.1 60 242 
rev CCGGATGATGTAGAGGTAGC 
Housekeeping genes  
GAPDH 
for GTC TTC ACT ACC ATG GAG AAG G 
NM001034034 60 197 
rev TCA TGG ATG ACC TTG GCC AG 
Ubiquitin 
for AGA TCC AGG ATA AGG AAG GCA T 
NM174133 62 198 
rev GCT CCA CCT CCA GGG TGA T 
1
ACoAC = acetyl-CoA carboxylase; FASN = fatty acid synthase; BDH1 = beta-hydroxybutyrate 
dehydrogenase 1; BDH2 = beta-hydroxybutyrate dehydrogenase 2; OXCT1 = succinyl-CoA:3-
ketoacid-coenzyme A transferase 1; CS = citrate synthase; GLUT1 = glucose transporter 1; GLUT4 = 
glucose transporter 4; GAPDH = glyceraldehyde 3-phosphate dehydrogenase. 
Figure 1 
Figure 2 
Figure 3 
Figure 4 
Figure 6 Figure 5 Figure 8 
Figure 7 
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Table 2. Means ± SEM of mRNA levels of housekeeping genes across time points and treatments. 
 
Genes
1 
Treatment
2 
Baseline 48h after infusions End of infusions 
GAPDH 
HyperB 18.6 ± 0.3 17.9 ± 0.2 17.3 ± 0.1 
NaCl 19.9 ± 0.7 19.3 ± 0.7 17.8 ± 0.7 
Ubiquitin 
HyperB 16.8 ± 0.4 17.2 ± 0.7 16.6 ± 0.2 
NaCl 19.1 ± 0.4 18.5 ± 0.3 18.1 ± 0.5 
1
GAPDH = glyceraldehyde 3-phosphate dehydrogenase. 
2
HyperB = Hyper beta-hydroxybutyrate group (n=5); NaCl = group of cows receiving physiological 
saline solution (n=8).
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Table 3. Milk yield, DMI of dairy cows infused with beta-hydroxybutyrate (HyperB, n=5) or saline 
(NaCl, n=8) before the start of the infusion (Day 0), second day of infusion (Day 2), and third day of 
infusion (day of LPS challenge). Values represent Mean ± SEM. 
 
Variables
1 Treatme
nt2 
Day 0 Day 2 
Day 3 (LPS 
challenge) 
P-
Valu
e, 
Treat
ment 
P-
Value, 
Time 
P-
Value, 
Treat
ment*
Time 
Milk yield, 
kg/d 
HyperB 24.9 ± 2.6 22.0 ± 2.6 13.0 ± 2.6 
0.94 <0.01 0.43 
NaCl 23.0 ± 2.3 20.6 ± 2.0 16.7 ± 2.0 
DMI, kg/d 
HyperB 19.9 ± 1.9 19.0 ± 1.9 8.5 ± 1.9 
0.41 <0.001 0.17 
NaCl 19.4 ± 1.7 18.1 ± 1.5 13.5 ± 1.5 
1
DMI= dry matter intake.
 
2
HyperB = Hyper beta-hydroxybutyrate group (n=5); NaCl = group of cows receiving physiological 
saline solution (n=8). 
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Table 4. Plasma variables concentration in dairy cows infused with beta-hydroxybutyrate (HyperB, 
n=5) or saline (NaCl, n=8) during the LPS challenge. Data are presented as least square means (LSM) 
± SEM of area under the curve (AUC) during 8 h. AUC was calculated according the Trapezoidal rule. 
Variable
 1
 
NaCl HyperB P-Value, 
NaCl vs. 
Baseline 
P-Value, 
HyperB 
vs. 
Baseline 
P-Value, 
HyperB 
vs. NaCl LSM ± SEM LSM ± SEM 
Glucose, mmol/L*h 4.3 ± 0.1 3.8 ± 0.1 0.01 0.30 0.02 
BHBA, mmol/L*h 0.4 ± 0.0 1.4 ± 0.1 0.03 <0.001 < 0.001 
NEFA, mmol/L*h 0.1 ± 0.0 0.1 ± 0.0 0.81 0.20 0.76 
Urea, mmol/L*h 4.0 ± 0.3 3.7 ± 0.3 0.02 0.07 0.44 
Cortisol, ng/mL*h 13.8 ± 1.5 14.7 ± 2.0 <0.001 0.001 0.73 
Insulin, mU/L*h 35.0 ± 5.4 34.8 ± 6.9 <0.001 0.01 0.97 
Glucagon, pg/ml*h 221.7 ± 15.3 161.2 ± 19.3 <0.001 0.08 0.03 
Insulin: Glucagon, 
molar ratio*h 
3.7 ± 0.7 4.4 ± 0.9 0.03 0.02 0.52 
1
BHBA = beta-hydroxybutyrate; NEFA = non-esterified fatty acids. 
2
HyperB = Hyper beta-hydroxybutyrate group (n=5); NaCl = group of cows receiving physiological 
saline solution (n=8).
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Table 5. Changes of mRNA abundance of genes related to mammary gland metabolism during 48 h 
infusion with beta-hydroxybutyrate (HyperB) or saline (NaCl). Delta (differences between before and 
48 h after the start of infusions). Values represent Mean ± SEM. 
Parameter Group Delta 
ANOVA 
(P-Value,group) 
Fatty acid synthesis related variables 
ACoAC 
HyperB -1.0 ± 0.5 
0.16 NaCl 0.0 ± 0.4 
    
FASN 
HyperB -1.0 ± 0.3
* 
0.13 NaCl -0.2 ± 0.5 
    
Beta-hydroxybutyrate metabolism related variables 
BDH1 
HyperB -0.9 ± 0.5 
0.49 NaCl -0.2 ± 0.6 
    
BDH2 
HyperB 0.1 ± 0.4 
0.53 NaCl 0.6 ± 0.6 
    
OXCT1 
HyperB -0.5 ± 0.3 
0.66 NaCl -0.2 ± 0.4 
    
Citrate synthase 
CS 
HyperB -0.2 ± 0.3 
0.86 NaCl -0.1 ± 0.4 
    
Glucose transporters 
GLUT1 
HyperB -0.4 ± 0.2 
0.88 NaCl -0.5 ± 0.7 
    
GLUT4 
HyperB 0.6 ± 0.5 
0.14 NaCl -0.4 ± 0.4 
    
1
ACoAC = acetyl-CoA carboxylase; FASN = fatty acid synthase; BDH1 = beta-hydroxybutyrate 
dehydrogenase 1; BDH2 = beta-hydroxybutyrate dehydrogenase 2; OXCT1 = succinyl-CoA:3-
ketoacid-coenzyme A transferase 1; CS = citrate synthase; GLUT1 = glucose transporter 1; GLUT4 = 
glucose transporter 4. 
2
HyperB = Hyper beta-hydroxybutyrate group (n=5); NaCl = group of cows receiving physiological 
saline solution (n=8). 
*Delta is different from 0 (P<0.05). 
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Table 6. Differences in mRNA abundance related to metabolism in mammary gland during the LPS 
challenge in LPS and control quarters in dairy cows infused with beta-hydroxybutyrate (HyperB) or 
saline (NaCl). Values are represented as mean ± SEM. 
Parameter Group 
LPS 
Delta (after LPS – 
before LPS) 
ANOVA 
(P-
Value,group) 
Control 
Delta (after LPS – 
before LPS) 
ANOVA 
(P-
Value,group) 
Fatty acid synthesis related variables 
ACoAC 
HyperB -0.9 ± 0.7 
0.66 
-0.6 ± 0.5 
0.58 NaCl -0.5 ± 0.6 -1.1 ± 0.7 
       
FASN 
HyperB -4.4 ± 0.7
* 
0.60 
-1.0 ± 1.2 
0.47 NaCl -3.8 ± 0.8
* 
-0.2 ± 0.5 
       
Beta-hydroxybutyrate metabolism related variables 
BDH1 
HyperB -1.4 ± 0.9 
0.37 
-1.6 ± 1.1 
0.96 NaCl -2.7 ± 0.9
* -1.7 ± 0.8 
       
BDH2 
HyperB -2.6 ± 0.4
* 
0.87 
-1.3 ± 0.5
* 
0.62 NaCl -2.4 ± 0.8
* 
-1.0 ± 0.5 
       
OXCT1 
HyperB -1.8 ± 0.3
* 
0.25 
0.3 ± 0.7 
0.56 NaCl -1.0 ± 0.5
* 1.7 ± 1.8 
       
Citrate synthase 
CS 
HyperB 0.5 ± 0.3 
0.05 
-0.4 ± 0.3 
0.35 NaCl -0.5 ± 0.3 0.3 ± 0.5 
       
Glucose transporters 
GLUT1 
HyperB -0.4 ± 0.4 
0.74 
0.4 ± 0.4 
0.85 NaCl -0.5 ± 0.2 0.3 ± 0.5 
       
GLUT4 
HyperB -0.9 ± 0.9 
0.24 
0.8 ± 0.8 
0.24 NaCl -2.0 ± 0.5
* 
0.4 ± 0.6 
       
1
ACoAC = acetyl-CoA carboxylase; FASN = fatty acid synthase; BDH1 = beta-hydroxybutyrate 
dehydrogenase 1; BDH2 = beta-hydroxybutyrate dehydrogenase 2; OXCT1 = succinyl-CoA:3-
ketoacid-coenzyme A transferase 1; CS = citrate synthase; GLUT1 = glucose transporter 1; GLUT4 = 
glucose transporter 4. 
2
HyperB = Hyper beta-hydroxybutyrate group (n=5); NaCl = group of cows receiving physiological 
saline solution (n=8). 
*Delta is different from 0 (P<0.05). 
